REG - Scancell Hlds - Dr Jean-Michel Cosséry appointed as Chairman

Scancell HoldingsAnnouncement

01/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230201:nRSA4842Oa&default-theme=true

RNS Number : 4842O  Scancell Holdings Plc  01 February 2023

1 February 2023

 

Scancell Holdings Plc

("Scancell" or the "Company")

 

 

Directorate Change

 

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the
Board

 

Jean-Michel brings 25 years of experience in the international pharmaceutical
and biotech industries

both in an executive and non-executive capacity

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, today announces the
appointment of Dr Jean-Michel Cosséry, as Non-Executive Chairman of the Board
of Directors with immediate effect. As previously announced, Dr John Chiplin
who has served as Chairman since 2016, will step down following Jean-Michel's
appointment. Jean-Michel will seek to drive Scancell's strategy for clinical
progress and commercial development of its novel immunotherapy vaccine and
antibody platforms.

 

Jean-Michel brings to Scancell over 25 years of experience in the
pharmaceutical and biotechnology industries and a sustained global track
record of success in commercial operations as well as in capital raising, US
and European public offerings, business development and M&A. Jean-Michel
was Vice President for North America Oncology at Eli Lilly, with
responsibility for commercialisation of the company's oncology portfolio.
Preceding this US-based position, he was Vice President and Managing Director
of the Eli Lilly's European Northern Hub, where he was Chair of the Eli Lilly
UK Board and a member of Lilly European Executive Committee. Prior to this
Jean-Michel served as VP and Chief Marketing Officer at GE Healthcare's Global
Headquarters.

 

Following his retirement from Eli Lilly in 2018, Jean-Michel has served on the
board of Kymab until their acquisition by Sanofi. He was also a member of the
Immunocore board prior to the company's Nasdaq listing. Jean-Michel currently
serves on the boards of Malin PLC, Exact Therapeutics AS, Eracal Therapeutics
and Sophia Genetics SA. He has also been Chair of The American Pharmaceutical
Group in the UK, as well as a board member of the Association of British
Pharmaceutical Industry. Jean-Michel holds an MBA from the Rotterdam School of
Management (Erasmus University), The Netherlands, as well as a PharmD and a
PhD in Nuclear Chemistry and Neurobiology from University Paris, France.

 

Dr John Chiplin, former Chairman of the Board of Scancell, commented:

"The last 7 years have been transformative for Scancell, I am leaving the
Company with strong management and exciting prospects ahead. I would like to
welcome Dr Jean-Michel Cosséry to Scancell, his extensive experience and
accomplishments speak volumes and his expertise in oncology and corporate
management will be invaluable as Scancell drive its immunotherapy products
through the clinic, with the aim to provide new treatment options for patients
with debilitating cancers."

 

Dr Jean-Michel Cosséry Chairman of the Board of Scancell, said:

"I am delighted to be joining the Scancell team at this pivotal time in the
Company's evolution and to build on the rich history it has in developing four
innovate platforms. I am excited about the clinical trials in progress and the
life changing improvement these important novel cancer therapies can bring to
patients, while enhancing shareholder value. I look forward to working with
the Board and the Senior Management Team as we seek to advance Scancell's
strategy."

 

Prof Lindy Durrant, Chief Executive Officer, Scancell, added:

"I speak on the behalf of all of Scancell that we are excited to welcome
Jean-Michel and to capitalise on his experience as we continue on our journey
to deliver the next stage of growth. I am deeply indebted to John Chiplin for
his hard work, support and boundless enthusiasm over the last 7 years which
has allowed us to build the Company into the strong business it is today."

 

Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies in relation to Jean-Michel Yves
Sylvain Cosséry, aged 63:

 

 

 Current Directorships             Previous Directorships (last 5 years)
 Malin Corporation Plc             Diurnal Group Limited
 Malin Life Sciences Holdings Ltd  Kymab Group Limited

 EXACT Therapeutics AS             Lilly USA LLC
 EraCal Therapeutics AG            Immunocore Limited
 SOPHiA GENETICS SA

 SCI Elyna

 

Dr Cossery does not have an interest in any ordinary shares of Scancell.

 

The Company confirms that there is no further information to be disclosed
pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.

 

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 (MAR).

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3727 1000
 Dr Jean-Michel Cosséry, Non-Executive Chairman                               +44 (0) 20 7886 2500
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 FTI Consulting                                                               +44 (0) 20 3727 1000
 Simon Conway/Rob Winder/Alex Davis

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAKZGFMNMFGFZM